HuLuc 63

Share this article with:

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.

Share It:
Contact XVIVO


PDL BioPharma

We couldn’t be happier with the animations XVIVO has created for our films. They just look terrific and everyone wants to know who did them for us.

Gino Del Guercio, Director, Boston Science Communications, Inc.